Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database

被引:3
|
作者
Liu, Leping [1 ]
Zheng, Hong [2 ]
Chen, Shanshan [3 ]
Wang, Shengfeng [4 ,5 ,6 ]
Yang, Minghua [1 ,6 ,7 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Pediat, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Hunan Canc Hosp, Dept Pharm, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp 3, Postdoctoral Res Stn Clin Med, Changsha, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, MOE Key Lab Rare Pediat Dis, Changsha, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Hunan Clin Res Ctr Pediat Canc, Changsha, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
low-molecular-weight heparin; heparin-induced thrombocytopenia; characteristics; treatments; pharmacovigilance; ENOXAPARIN-INDUCED THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; SKIN NECROSIS; PATIENT; RIVAROXABAN; MANAGEMENT; THROMBOSIS; ARTERIAL; FONDAPARINUX;
D O I
10.3389/fphar.2023.1247253
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are commonly used anticoagulants for the management of arterial and venous thromboses. However, it is crucial to be aware that LMWH can, in rare cases, lead to a dangerous complication known as heparin-induced thrombocytopenia (HIT). The objective of this study was to evaluate the pharmacovigilance and clinical features of HIT associated with LMWH, as well as identify treatment strategies and risk factors to facilitate prompt management.Methods: We extracted adverse event report data from the FDA Adverse Event Reporting System (FAERS) database for pharmacovigilance assessment. Case reports on LMWH-induced thrombocytopenia dated up to 20 March 2023 were collected for retrospective analysis.Results: Significantly elevated reporting rates of HIT were shown in adverse event (AE) data of LMWHs in the FAERS database, while tinzaparin had a higher proportional reporting ratio (PRR) and reporting odds ratio (ROR) than other LMWHs, indicating a greater likelihood of HIT. Case report analysis indicated that a total of 43 patients showed evidence of LMWH-induced thrombocytopenia with a median onset time of 8 days. Almost half of the events were caused by enoxaparin. LMWHs were mainly prescribed for the treatment of embolism and thromboprophylaxis of joint operation. Patients with a history of diabetes or surgery appeared to be more susceptible to HIT. Clinical symptoms were mostly presented as thrombus, skin lesion, and dyspnea. Almost 90% of the patients experienced a platelet reduction of more than 50% and had a Warkentin 4T score of more than 6, indicating a high likelihood of HIT. In all patients, LMWHs that were determined to be the cause were promptly withdrawn. Following the discontinuation of LMWHs, almost all patients were given alternative anticoagulants and eventually achieved recovery.Conclusion: LMWH-induced thrombocytopenia is rare but serious, with increased risk in patients with diabetes or a surgical history. Prompt recognition and management are crucial for the safe use of LMWHs.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Low incidence of heparin-induced skin lesions in orthopedic surgery patients with low-molecular-weight heparins
    Schindewolf, M.
    Paulik, M.
    Kroll, H.
    Kaufmann, R.
    Wolter, M.
    Boehncke, W. -H.
    Lindhoff-Last, E.
    Recke, A.
    Ludwig, R. J.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (08) : 1016 - 1024
  • [22] Heparin "hitts" again - Acute thrombocytopenia caused by the erroneous re-exposition with a low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombosis (HITT)
    Goti, F
    Korte, W
    Gianom, D
    Decurtins, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 57 (12) : 917 - 918
  • [24] Use of low molecular weight heparin in patients with heparin-induced thrombocytopenia undergoing carotid endarterectomy
    Gottlieb, A
    Tabares, AH
    Levy, P
    Sprung, J
    KottkeMarchant, K
    Schoenwald, PK
    ANESTHESIOLOGY, 1996, 85 (03) : 678 - 681
  • [25] PREVALENCE OF HEPARIN-INDUCED THROMBOCYTOPENIA AFTER ACUTE CORONARY SYNDROME TREATED WITH LOW MOLECULAR WEIGHT HEPARIN VERSUS UNFRACTIONED HEPARIN
    Shoukat, Farkhanda
    Fatima, Nousheen
    Noreen
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (09): : 9416 - 9420
  • [26] Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin
    Lindhoff-Last, E
    Nakov, R
    Misselwitz, F
    Breddin, HK
    Bauersachs, R
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (04) : 1137 - 1142
  • [27] Established Venous Thromboembolism Therapies: Heparin, Low Molecular Weight Heparins, and Vitamin K Antagonists, with a Discussion of Heparin-Induced Thrombocytopenia
    Pendleton, Robert C.
    Rodgers, George M.
    Hull, Russell D.
    CLINICS IN CHEST MEDICINE, 2010, 31 (04) : 691 - +
  • [28] Three cases of heparin-induced thrombocytopenia associated with polytrauma
    Yumoto, Tetsuya
    Sato, Keiji
    Fujii, Nobuharu
    Kinami, Yo
    Tsukahara, Kohei
    Ugawa, Toyomu
    Ichiba, Shingo
    Ujike, Yoshihito
    ACUTE MEDICINE & SURGERY, 2016, 3 (01): : 46 - 49
  • [29] Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients
    Junqueira, Daniela R.
    Zorzela, Liliane M.
    Perini, Edson
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (04):
  • [30] Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?
    Al-Eidan, Fahad A. S.
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2015, 7